ArticleCancer pathogenesis and therapy2024

Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial.

Changgong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.